Titan Pharmaceuticals (NASDAQ:TTNP) & Moderna (NASDAQ:MRNA) Critical Contrast

Titan Pharmaceuticals (NASDAQ:TTNP) and Moderna (NASDAQ:MRNA) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, valuation, institutional ownership, risk, profitability, dividends and analyst recommendations.

Valuation & Earnings

This table compares Titan Pharmaceuticals and Moderna’s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Titan Pharmaceuticals $3.61 million 7.33 -$16.46 million ($0.72) -0.38
Moderna $60.21 million 369.13 -$514.02 million ($1.55) -38.63

Titan Pharmaceuticals has higher earnings, but lower revenue than Moderna. Moderna is trading at a lower price-to-earnings ratio than Titan Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.


This table compares Titan Pharmaceuticals and Moderna’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Titan Pharmaceuticals -437.91% -1,909.37% -190.56%
Moderna -963.84% -37.49% -29.24%

Institutional & Insider Ownership

3.5% of Titan Pharmaceuticals shares are held by institutional investors. Comparatively, 52.0% of Moderna shares are held by institutional investors. 0.9% of Titan Pharmaceuticals shares are held by insiders. Comparatively, 29.2% of Moderna shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Volatility and Risk

Titan Pharmaceuticals has a beta of 0.88, indicating that its share price is 12% less volatile than the S&P 500. Comparatively, Moderna has a beta of 0.67, indicating that its share price is 33% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent recommendations for Titan Pharmaceuticals and Moderna, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Titan Pharmaceuticals 0 0 1 0 3.00
Moderna 0 1 8 0 2.89

Titan Pharmaceuticals currently has a consensus target price of $1.00, indicating a potential upside of 261.53%. Moderna has a consensus target price of $67.70, indicating a potential upside of 13.08%. Given Titan Pharmaceuticals’ stronger consensus rating and higher possible upside, equities research analysts plainly believe Titan Pharmaceuticals is more favorable than Moderna.

About Titan Pharmaceuticals

Titan Pharmaceuticals, Inc., a pharmaceutical company, develops proprietary therapeutics for the treatment of serious medical disorders. It develops products based on ProNeura, a proprietary long-term drug delivery platform that focuses primarily on treatments for chronic diseases. The company offers Probuphine, a product candidate for maintenance treatment of opioid dependence, which maintains a stable, around the clock blood level of the drug buprenorphine in patients for six months following a single treatment. It also develops ProNeura-Ropinirole, an implant to provide delivery of ropinirole, a dopamine agonist for the treatment of Parkinson's disease; and triiodothyronine, an implant for the treatment of hypothyroidism. The company has a collaboration with Nevada Center for Behavioral Health to evaluate a medication-assisted treatment program utilizing Probuphine (buprenorphine) implant for Opioid Use Disorder (OUD) patients. Titan Pharmaceuticals, Inc. was founded in 1992 and is based in South San Francisco, California.

About Moderna

Moderna, Inc., a clinical stage biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, and cardiovascular diseases. As of February 15, 2019 the company had 11 programs in clinical trials and a total of 20 development candidates in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. It has strategic alliances with AstraZeneca, Merck & Co., Vertex Pharmaceuticals, Biomedical Advanced Research and Development Authority, Defense Advanced Research Projects Agency, and Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Receive News & Ratings for Titan Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Titan Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.